shRNA-armed conditionally replicative adenoviruses: a promising approach  for cancer therapy

Jie Zhang; Meng Ding; Kai Xu; Lijun Mao; Junian Zheng

doi:10.18632/oncotarget.8035

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy

Jie Zhang, Meng Ding, Kai Xu, Lijun Mao and Junian Zheng _

PDF | HTML | How to cite

Oncotarget. 2016; 7:29824-29834. https://doi.org/10.18632/oncotarget.8035

Metrics: PDF 2391 views | HTML 3581 views | ?

Abstract

Jie Zhang1, Meng Ding1, Kai Xu1, Lijun Mao1,2 and Junian Zheng1

1 Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou, China

2 Department of Urinary Surgery, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, China

Correspondence:

Lijun Mao, email:

Junian Zheng, email:

Keywords: conditionally replicating adenoviruses, RNA interference, cancer, target therapy

Received: December 09, 2015 Accepted: February 15, 2016 Published: March 10, 2016

Abstract

The small-interfering RNAs (siRNAs) have been employed to knockdown the expression of cancer-associated genes and shown some promise in cancer therapy. However, synthetic siRNA duplexes or plasmid mediated delivery of siRNAs have several problems, such as short half-life, low transfection efficiency and cytotoxicity associated with transfection. Conditionally replicating adenovirus (CRAds) as the delivery vector for short hairpin RNAs (shRNAs) could overcome these limitations and have shown augmented anti-tumor effects in experimental studies and preclinical trials. In this review, we summarize recent progress in the development of CRAds-shRNA for cancer treatment. Combination of CRAds-shRNA with chemotherapeutics, radiation, dendritic cells, monoclonal antibodies and small-molecule inhibitors will be necessary to eradicate cancer cells and cancer stem cells and achieve superior outcomes. The use of CRAd platform for efficient delivery of shRNAs and foreign genes will open a new avenue for cancer therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8035

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy

Abstract